Production of study material of XEN-D0501 is underway and is expected to be completed before the summer, whereupon Pila Pharma can start a three-month toxicology study with the drug candidate. In parallel with the study preparations, the company implements organizational changes and strengthens its team. Susanne Rugh, a long-time veteran of Novo Nordisk, is now taking over the role of project director for the diabetes program.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/novo-veteran-strengthens-pila-pharma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/pila-pharma/r/biostock--novo-veteran-strengthens-pila-pharma,c3502223

(c) 2022 Cision. All rights reserved., source Press Releases - English